SL32112: Specialised integrated unit 5: neurology and mental health
[Page last updated: 03 June 2024]
| Academic Year: | 2024/25 |
| Owning Department/School: | Department of Life Sciences |
| Credits: | 10 [equivalent to 20 CATS credits] |
| Notional Study Hours: | 200 |
| Level: | Honours (FHEQ level 6) |
| Period: |
|
| Assessment Summary: | CWOG 25%, CWSI 25%, EXCB 50% |
| Assessment Detail: |
|
| Supplementary Assessment: |
|
| Requisites: | |
| Learning Outcomes: |
By the end of the unit, you will be able to:
1. Describe the aetiology, epidemiology, pathophysiology and clinical symptoms of major neurological disease and mental health disorders and how they are diagnosed and treated.
2. Explain the pharmacology and mechanisms of action of medicines used for the treatment of neurological and mental health disorders and be able to critically evaluate structure-activity relationships, dose-response relationships and biomarkers of treatment and clinical outcomes.
3. Describe the key biopharmaceutical (formulation and pharmacokinetic) factors that determine the performance of medicines used to treat neurological and mental health disorders.
4. Identify and critically evaluate evidence-based approaches for the management of patients with neurological and mental health disorders.
5. Evaluate the role of the pharmacist in prescribing, administering and monitoring medication for patients with neurological and mental health disorders.
6. Make appropriate clinical decisions in support of patients with neurological and mental health disorders.
7. Apply complex structured consultation skills to the conditions studied in this unit.
8. Reflect on their own practice in supporting patients with these diseases, carers, and other healthcare professionals and identify areas for continuous improvement. |
| Synopsis: | This unit will provide you with a comprehensive, integrated understanding of the design and development of medicines, their pharmacological actions in the body and the evidence-based approach to prescribing for patients with the aim of promoting safe and effective outcomes in neurology and mental health. It also considers non-pharmacological interventions evidenced to be effective in neurological and mental health conditions. |
| Content: | Clinical Introduction and overview of therapeutic area - Problem-based learning case
Transdermal and controlled drug delivery, implantable devices
Blood brain barrier distribution and other biopharmaceutics factors relevant to the therapeutic area.
Rate control processes in pharmacokinetics. Effect of physiological and disease factor on performance of oral formulations
Pharmacokinetics of prodrugs
Neurotransmitters
Analgesics
Cannabinoids
Centrally acting anti-obesity agents
Design and development of drugs for treating neurological and mental health disorders
Strategies in pain management
Headache and migraine
Stroke
Epilepsy
Motor disorders - Parkinson's disease, multiple sclerosis, motor neurone disease, myasthenia gravis
Anxiety
Sleep and hypnotics
Depression
Psychosis, schizophrenia, bipolar disorder
Memory & Alzheimer's disease
Anorexia and other eating disorders
Consent and capacity in neurological and mental health disorders
Recognising mental health symptoms
The principles of talking therapies, mindfulness and cognitive behavioural therapy (CBT)
The role of community mental health teams
Clinical decision-making in neurology and mental health
Simulation and practice-based learning in neurology and mental health |
| Course availability: |
SL32112 is a Designated Essential Unit on the following courses:Department of Life Sciences
|
Notes:
|